Biotech

All Articles

Merck quits period 3 TIGIT trial in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT plan has actually suffered another obstacle. Months after shuttering a stage...

After a difficult year, Exscientia folds in to Recursion

.After a year described by pipe cuts, the shift of its own CEO as well as layoffs, Exscientia will c...

Cullinan, after $25M offer, return bispecific to Harbour

.Cullinan Rehab was actually excited good enough with Harbour BioMed's bispecific immune activator t...

A closer check out Intense Biotech's Tough 15

.Within this full week's incident of "The Top Pipe," we are actually diving right into Brutal Biotec...

Lilly encounters phase 2 failure of tau-targeting med

.The confetti is still flying from Eli Lilly's gathering celebrating the approval of Alzheimer's ail...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of significant management hirings, firings a...

Lykos will definitely talk to FDA to reexamine its own selection adhering to being rejected of MDMA treatment for trauma

.Following an inadequate revealing for Lykos Therapeutics' MDMA prospect for post-traumatic stress d...

AN 2 halves headcount, ceases period 3 trial after records let down

.AN2 Therapeutics is re-thinking its service in response to poor midphase data, vowing to give up ha...

Merck spends $700M for bispecific, spying autoimmune opening as well as possibility to test Amgen in cancer

.Merck &amp Co. is paying out $700 million beforehand to test Amgen in a blood cancer market. The of...

Gilead pays for J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences about to an FDA decision for its liver ailment drug seladelpar, the busi...